{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:31Z","timestamp":1740107431975,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CASS Foundation, Australia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00280-022-04435-1","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T08:02:51Z","timestamp":1650700971000},"page":"773-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells"],"prefix":"10.1007","volume":"89","author":[{"given":"Oula C.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don R.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5477-8721","authenticated-orcid":false,"given":"Benny J.","family":"Evison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"issue":"2","key":"4435_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/med.21364","volume":"36","author":"BJ Evison","year":"2016","unstructured":"Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2016) Mitoxantrone, more than just another topoisomerase II poison. Med Res Rev 36(2):248\u2013299. https:\/\/doi.org\/10.1002\/med.21364","journal-title":"Med Res Rev"},{"issue":"9","key":"4435_CR2","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/0006-2952(90)90237-F","volume":"40","author":"PJ Smith","year":"1990","unstructured":"Smith PJ, Morgan SA, Fox ME, Watson JV (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 40(9):2069\u20132078","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"4435_CR3","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1093\/nar\/27.14.2918","volume":"27","author":"BS Parker","year":"1999","unstructured":"Parker BS, Cullinane C, Phillips DR (1999) Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res 27(14):2918\u20132923","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"4435_CR4","doi-asserted-by":"publisher","first-page":"18814","DOI":"10.1074\/jbc.M400931200","volume":"279","author":"BS Parker","year":"2004","unstructured":"Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR (2004) A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J Biol Chem 279(18):18814\u201318823. https:\/\/doi.org\/10.1074\/jbc.M400931200","journal-title":"J Biol Chem"},{"issue":"2","key":"4435_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00262337","volume":"6","author":"TH Corbett","year":"1981","unstructured":"Corbett TH, Griswold DP Jr, Roberts BJ, Schabel FM Jr (1981) Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol 6(2):161\u2013168","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4435_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1021\/jm00032a018","volume":"37","author":"AP Krapcho","year":"1994","unstructured":"Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP, Giuliani FC et al (1994) 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem 37(6):828\u2013837","journal-title":"J Med Chem"},{"issue":"5","key":"4435_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1634\/theoncologist.2013-0020","volume":"18","author":"E Pean","year":"2013","unstructured":"Pean E, Flores B, Hudson I, Sjoberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F (2013) The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin\u2019s B cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 18(5):625\u2013633. https:\/\/doi.org\/10.1634\/theoncologist.2013-0020","journal-title":"Oncologist"},{"issue":"3","key":"4435_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10637-007-9037-8","volume":"25","author":"E Cavalletti","year":"2007","unstructured":"Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F (2007) Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 25(3):187\u2013195. https:\/\/doi.org\/10.1007\/s10637-007-9037-8","journal-title":"Invest New Drugs"},{"key":"4435_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.reprotox.2014.02.006","volume":"46","author":"M Longo","year":"2014","unstructured":"Longo M, Della Torre P, Allievi C, Morisetti A, Al-Fayoumi S, Singer JW (2014) Tolerability and toxicological profile of pixantrone (Pixuvri(R)) in juvenile mice. Comparative study with doxorubicin. Reprod Toxicol 46:20\u201330. https:\/\/doi.org\/10.1016\/j.reprotox.2014.02.006","journal-title":"Reprod Toxicol"},{"issue":"1","key":"4435_CR10","first-page":"30","volume":"48","author":"P De Isabella","year":"1995","unstructured":"De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC et al (1995) Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 48(1):30\u201338","journal-title":"Mol Pharmacol"},{"issue":"2","key":"4435_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0006-2952(93)90413-Q","volume":"46","author":"LA Zwelling","year":"1993","unstructured":"Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP (1993) Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol 46(2):265\u2013271","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"4435_CR12","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1093\/nar\/gkm285","volume":"35","author":"BJ Evison","year":"2007","unstructured":"Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM (2007) Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 35(11):3581\u20133589. https:\/\/doi.org\/10.1093\/nar\/gkm285","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4435_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ijc.2910490113","volume":"49","author":"A Rephaeli","year":"1991","unstructured":"Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A (1991) Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer J Int Cancer 49(1):66\u201372","journal-title":"Int J Cancer J Int Cancer"},{"issue":"5","key":"4435_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10637-006-6213-1","volume":"24","author":"A Rephaeli","year":"2006","unstructured":"Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, Phillips DR, Cutts SM, Haas-Kogan D, Nudelman A (2006) The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs 24(5):383\u2013392. https:\/\/doi.org\/10.1007\/s10637-006-6213-1","journal-title":"Invest New Drugs"},{"issue":"12","key":"4435_CR15","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/1535-7163.Mct-05-0087","volume":"4","author":"M Entin-Meer","year":"2005","unstructured":"Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4(12):1952\u20131961. https:\/\/doi.org\/10.1158\/1535-7163.Mct-05-0087","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"4435_CR16","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1021\/jm901894c","volume":"53","author":"OC Mansour","year":"2010","unstructured":"Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM (2010) New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. J Med Chem 53(19):6851\u20136866. https:\/\/doi.org\/10.1021\/jm901894c","journal-title":"J Med Chem"},{"issue":"5A","key":"4435_CR17","first-page":"3189","volume":"20","author":"GI Salti","year":"2000","unstructured":"Salti GI, Das Gupta TK, Constantinou AI (2000) A novel use for the comet assay: detection of topoisomerase II inhibitors. Anticancer Res 20(5A):3189\u20133193","journal-title":"Anticancer Res"},{"issue":"1","key":"4435_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2307\/3577279","volume":"117","author":"PL Olive","year":"1989","unstructured":"Olive PL (1989) Cell proliferation as a requirement for development of the contact effect in Chinese hamster V79 spheroids. Radiat Res 117(1):79\u201392","journal-title":"Radiat Res"},{"issue":"1","key":"4435_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2307\/3577587","volume":"122","author":"PL Olive","year":"1990","unstructured":"Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the \u201ccomet\u201d assay. Radiat Res 122(1):86\u201394","journal-title":"Radiat Res"},{"key":"4435_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4","journal-title":"Adv Enzyme Regul"},{"issue":"41","key":"4435_CR21","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.1021\/bi00105a020","volume":"30","author":"WG Harker","year":"1991","unstructured":"Harker WG, Slade DL, Drake FH, Parr RL (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30(41):9953\u20139961","journal-title":"Biochemistry"},{"issue":"11","key":"4435_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.bcp.2011.08.013","volume":"82","author":"BJ Evison","year":"2011","unstructured":"Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochem Pharmacol 82(11):1604\u20131618. https:\/\/doi.org\/10.1016\/j.bcp.2011.08.013","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4435_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.dnarep.2011.11.002","volume":"11","author":"C Valiathan","year":"2012","unstructured":"Valiathan C, McFaline JL, Samson LD (2012) A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects. DNA Repair 11(1):92\u201398. https:\/\/doi.org\/10.1016\/j.dnarep.2011.11.002","journal-title":"DNA Repair"},{"issue":"1","key":"4435_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1124\/mol.108.045625","volume":"74","author":"BJ Evison","year":"2008","unstructured":"Evison BJ, Chiu F, Pezzoni G, Phillips DR, Cutts SM (2008) Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 74(1):184\u2013194. https:\/\/doi.org\/10.1124\/mol.108.045625","journal-title":"Mol Pharmacol"},{"issue":"4","key":"4435_CR25","first-page":"1125","volume":"37","author":"J Thorndike","year":"1977","unstructured":"Thorndike J, Beck WS (1977) Production of formaldehyde from N5-methyltetrahydrofolate by normal and leukemic leukocytes. Can Res 37(4):1125\u20131132","journal-title":"Can Res"},{"issue":"3","key":"4435_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058957","volume":"8","author":"J Liu","year":"2013","unstructured":"Liu J, Liu FY, Tong ZQ, Li ZH, Chen W, Luo WH, Li H, Luo HJ, Tang Y, Tang JM, Cai J, Liao FF, Wan Y (2013) Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats. PLoS ONE 8(3):e58957. https:\/\/doi.org\/10.1371\/journal.pone.0058957","journal-title":"PLoS ONE"},{"issue":"3","key":"4435_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00280-005-0060-1","volume":"57","author":"MW DeGregorio","year":"2006","unstructured":"DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW (2006) Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 57(3):335\u2013342. https:\/\/doi.org\/10.1007\/s00280-005-0060-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4435_CR28","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1002\/jps.21319","volume":"97","author":"SS Dhareshwar","year":"2008","unstructured":"Dhareshwar SS, Stella VJ (2008) Your prodrug releases formaldehyde: should you be concerned? No! J Pharm Sci 97(10):4184\u20134193. https:\/\/doi.org\/10.1002\/jps.21319","journal-title":"J Pharm Sci"},{"issue":"5","key":"4435_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9(5):338\u2013350. https:\/\/doi.org\/10.1038\/nrc2607","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"4435_CR30","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","volume":"66","author":"LP Swift","year":"2006","unstructured":"Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Can Res 66(9):4863\u20134871. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3410","journal-title":"Can Res"},{"issue":"16","key":"4435_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn439","volume":"36","author":"KE Coldwell","year":"2008","unstructured":"Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR (2008) Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res 36(16):e100. https:\/\/doi.org\/10.1093\/nar\/gkn439","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4435_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.lungcan.2004.03.002","volume":"45","author":"T Reid","year":"2004","unstructured":"Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45(3):381\u2013386. https:\/\/doi.org\/10.1016\/j.lungcan.2004.03.002","journal-title":"Lung Cancer"},{"issue":"9","key":"4435_CR33","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H (2021) Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B 11(9):2726\u20132737. https:\/\/doi.org\/10.1016\/j.apsb.2021.01.004","journal-title":"Acta Pharm Sin B"},{"issue":"43","key":"4435_CR34","doi-asserted-by":"publisher","first-page":"10217","DOI":"10.1039\/c6ob02100j","volume":"14","author":"SK Konda","year":"2016","unstructured":"Konda SK, Kelso C, Medan J, Sleebs BE, Phillips DR, Cutts SM, Collins JG (2016) Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts. Org Biomol Chem 14(43):10217\u201310221. https:\/\/doi.org\/10.1039\/c6ob02100j","journal-title":"Org Biomol Chem"},{"issue":"20","key":"4435_CR35","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1039\/c6ob00561f","volume":"14","author":"SK Konda","year":"2016","unstructured":"Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG (2016) Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA. Org Biomol Chem 14(20):4728\u20134738. https:\/\/doi.org\/10.1039\/c6ob00561f","journal-title":"Org Biomol Chem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04435-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:03:48Z","timestamp":1653555828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04435-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4435"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04435-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.E. is an employee of Nyrada Inc. and declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}